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Abstract Cardioprotection against ischaemia/reperfusion
injury in mice can be achieved by delayed ischaemic
postconditioning (IPost) applied as late as 30 min after the
onset of reperfusion. We determined the efficacy of
delayed IPost in a rat model of myocardial infarction (MI)
and investigated potential underlying mechanisms of this
phenomenon. Rats were subjected to 20, 30 or 45 min of
coronary artery occlusion followed by 120 min of reper-
fusion (I/R). Immediate and early IPost included six cycles
of I/R (10/10 s) applied 10 s or 10 min after reperfusion
onset. In the second series of experiments, the rats were
subjected to 30 min of coronary occlusion followed by
IPost applied 10 s, 10, 30, 45 or 60 min after the onset of
reperfusion. Immediate and early IPost (applied 10 s or
10 min of reperfusion) established cardioprotection only
when applied after a period of myocardial ischaemia last-
ing 30 min. Delayed IPost applied after 30 or 45 min of
reperfusion reduced infarct sizes by 36 and 41 %, respec-
tively (both P \ 0.01). IPost applied 60 min after
reperfusion onset was ineffective. Inhibition of RISK
pathway (administration of ERK1/2 inhibitor PD-98059 or
PI3K inhibitor LY-294002) abolished cardioprotection
established by immediate IPost but had no effect on car-
dioprotection conferred by early IPost. Blockade of SAFE
pathway using JAK/STAT inhibitor AG490 had no effect
on the immediate or early IPost cardioprotection. Blockade
of mitochondrial KATP (mitoKATP) channels (with 5-Hy-
droxydecanoate) abolished cardioprotection achieved by
immediate and early IPost, but had no effect on cardio-
protection when IPost was applied 30 or 45 min into the
reperfusion period. Immediate IPost increased phosphory-
lation of PI3K-AKT and ERK1/2. Early or delayed IPost
had no effect on phosphorylation of PI3K-AKT, ERK1/2 or
STAT3. These data show that in the rat model, delayed
IPost confers significant cardioprotection even if applied
45 min after onset of reperfusion. Cardioprotection
induced by immediate and early postconditioning involves
recruitment of RISK pathway and/or mitoKATP channels,
while delayed postconditioning appears to rely on a dif-
ferent mechanism.
Keywords Ischaemia and reperfusion injury  MitoKATP
channels  Myocardial infarction  Postconditioning 
Preconditioning  RISK and SAFE pathways
Introduction
Infarct size is the major determinant of prognosis in
patients with an acute myocardial infarction (MI). The
landmark experimental study by Reimer et al. [34]
described the wavefront phenomenon of myocardial cell
death by showing that infarct size is dependent upon the
duration of myocardial ischaemia. Restitution of blood
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supply to an ischaemic area is, therefore, crucial for tissue
survival but it also results in a cascade of harmful events
known as lethal reperfusion injury [29]. The latter is
defined as the death of cardiomyocytes that are still viable
at the end of the ischaemic period. Clinical therapies aimed
to reduce the extent of myocardial ischaemia/reperfusion
injury are still limited to thrombolysis or immediate per-
cutaneous coronary intervention. In experimental studies,
Zhao et al. [51] used a dog model of MI and demonstrated
that the infarct size could be significantly reduced when
three brief cycles of ischaemia/reperfusion (30/30 s) are
applied after the onset of reperfusion which followed a
60 min period of ischaemia. This immediate ischaemic
postconditioning (IPost) was also found to be effective in
conferring cardioprotection in isolated hearts and different
animal models [40]. However, there are also discordant
reports showing that IPost fails to establish cardioprotec-
tion [6, 26, 38, 40]. Human studies assessing the efficacy of
immediate IPost demonstrated significant reduction [25,
27, 46, 47], modest [41] or no effect [7, 24, 45] of IPost on
infarct size.
The time window for protective intervention(s) during
reperfusion has important implications in terms of under-
standing the mechanisms underlying myocardial ischae-
mia/reperfusion injury and clinical usefulness of IPost. In
support of the prevailing concept, stating that any cardio-
protective strategy should be applied immediately after the
onset of reperfusion [32], Kin et al. [22] demonstrated in a
rat model of MI that IPost is not effective when applied
1 min into the reperfusion period. However, recent data
obtained in mice suggest that cardioprotection can still be
established by delayed IPost applied as late as 30 min after
reperfusion onset [35]. While rejecting the idea of an
instantaneous reperfusion injury, Roubille et al. [35] pro-
posed the theory of a dynamic wavefront of reperfusion-
induced cell death which develops over a certain period of
time during reperfusion period.
Endogenous mechanisms of cardioprotection recruited
early in reperfusion by immediate IPost involve activation
of Reperfusion Injury Salvage Kinase (RISK) and/or Sur-
vival Activating Factor Enhancement (SAFE) signalling
pathways leading to inhibition of the mitochondrial per-
meability transition pore (mPTP) [13, 18] and activation of
mitochondrial ATP-dependent potassium (mitoKATP)
channels [18]. RISK pathway includes pro-survival kinase
cascades among which mitogen-activated protein kinase
p44/p42 (ERK1/2) and phosphatidylinositol 3-kinase AKT
(PI3K/AKT) play important roles [14]. SAFE pathway
includes tumour necrosis factor-a receptors and janus-
activated kinase (JAK) signal transducer and activator of
transcription (STAT) [23].
In this study, we determined the efficacy of delayed
IPost in a rat model of MI (with various ischaemia
durations) and investigated potential underlying mecha-
nisms of this phenomenon by pharmacological blockade of
mitoKATP channels, RISK and SAFE pathways, as well as
Western blot analysis of RISK and SAFE activation.
Methods
All the experiments were performed in accordance with the
European Commission Directive 86/609/EEC (European
Convention for the Protection of Vertebrate Animals used
for Experimental and Other Scientific Purposes) and the
UK Home Office (Scientific Procedures) Act (1986) with
project approval from the respective Institutional Animal
Care and Use Committees.
Animal preparation
Adult male Wistar rats (280–320 g) were anaesthetized
with pentobarbital sodium (induction 60 mg kg-1 i.p.;
maintenance 10–15 mg kg-1 h-1 i.v.). Adequate anaes-
thesia was ensured by maintaining stable levels of arterial
blood pressure and heart rate and confirmed by the absence
of a withdrawal response to a paw pinch. The right carotid
artery and left jugular vein were cannulated for measure-
ment of the arterial blood pressure and administration of
anaesthetic or test compounds, respectively. The trachea
was cannulated, and the animal was ventilated with room air
using a positive pressure ventilator with a tidal volume of
*8–10 ml kg-1 and a ventilator frequency of
*60 strokes min-1. A standard lead II ECG was recorded
and the body temperature was maintained at 37.0 ± 0.2 C.
Model of myocardial infarction
The heart was exposed via a left thoracotomy and a 5–0
monofilament polypropylene suture was passed around the
left anterior descending coronary artery (LAD) to induce
occlusion(s). Myocardial ischaemia lasting 20, 30 or
45 min was induced by LAD ligation and was followed by
120 min of reperfusion.
Measurements of infarct size
At the end of the reperfusion period, the LAD was re-occlu-
ded, and Evans Blue dye solution was injected into the jugular
vein for the assessment of the area at risk. The animal was
then given an anaesthetic overdose, the heart was excised, and
the left ventricle (LV) was isolated, frozen and sectioned into
5–6 transverse slices from apex to the base. The area at risk
was demarcated by the absence of Evans Blue staining. LV
slices were then incubated with 1 % 2,3,5-triphenyltetrazo-
lium chloride (TTC) in Tris buffer (pH 7.4) for 15 min at
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37 C and fixed (4 % formalin). Viable myocardium is
stained red by TTC, whereas necrotic myocardium appears
pale yellow. The area at risk and the necrotic area were
determined by computerised planimetry, normalised to the
weight of each slice, with the degree of necrosis (i.e. infarct
size) expressed as the percentage of area at risk.
Fig. 1 a Illustration of the experimental protocols. Myocardial
infarction (MI) was induced in anaesthetized rats by left descending
coronary artery (LAD) occlusion followed by 120 min of reperfusion
(I/R). Ischaemic postconditioning (IPost) included six cycles of I/R
(10 s/10 s) starting 10 s (IPost1000) or 10 min (IPost100) after the
onset of reperfusion which followed periods of LAD occlusion lasting
either 20 min [IPost1000(200), IPost100(200)], 30 min [IPost1000(300),
IPost100(300)] or 45 min [IPost1000(450), IPost100(450)]. b Illustration
of the experimental protocols. MI was induced by 30 min of LAD
occlusion followed by 120 min of reperfusion. IPost was applied 10 s
(IPost1000), 10 min (IPost100), 30 min (IPost300), 45 min (IPost450) or
60 min (IPost600) after the onset of reperfusion. c IPost effectively
reduces myocardial ischaemia/reperfusion injury only when applied
after a period of LAD occlusion lasting 30 min. d IPost reduces
myocardial ischaemia/reperfusion injury when applied 10 s, 10, 30 or
45 min after the onset of reperfusion which followed periods of LAD
occlusion lasting 30 min. Infarct sizes are presented as percentages of
the areas at risk. Individual data and mean ± SD are shown.
**P \ 0.01; *P \ 0.05; n.s.—not significant
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Experimental protocols
Protocol 1. To determine the efficacy of immediate,
early and delayed IPost in conferring cardioprotection
against myocardial ischaemia/reperfusion injury and its
dependence upon the duration of the ischaemic period
Myocardial ischaemia/reperfusion injury was induced by
either 20 min (n = 6), 30 min (n = 8), or 45 min (n = 8)
of LAD occlusion followed by 120 min of reperfusion (I/
R). Immediate and early IPost included six cycles of I/R
(10 s/10 s) starting: 10 s (IPost1000) or 10 min (IPost100)
following periods of ischaemia lasting either 20 min
(n = 6), 30 min (n = 7) or 45 min (n = 6), respectively
(Fig. 1a). To determine the efficacy of delayed IPost in
this model, six cycles of I/R (10 s/10 s) were applied
30 min (IPost300, n = 7), 45 min (IPost450, n = 8) or
60 min (IPost600, n = 6) after the onset of reperfusion
which followed period of ischaemia lasting 30 min
(Fig. 1b).
Protocol 2. To investigate the role of RISK and SAFE
pathways in cardioprotection established by IPost.
Myocardial ischaemia/reperfusion injury was induced
by 30 min (n = 10) of LAD occlusion followed by
120 min of reperfusion. The control group received vehicle
(5 % DMSO in saline) injected i.v. 15 min before reper-
fusion. Immediate and early IPost protocols included six
cycles of I/R (10 s/10 s) starting, respectively, 10 s
(IPost1000, n = 6) or 10 min (IPost100, n = 7) after the
onset of reperfusion (Fig. 2a). ERK1/2 inhibitor PD-98059
(0.3 mg kg-1, i.v.) was administered 15 or 25 min after the
start of the ischaemic period in animals subjected to IPost
applied 10 s (PD-IPost1000 group; n = 6) or 10 min after
reperfusion onset (PD-IPost100 group; n = 7), respectively.
PI3K inhibitor LY-294002 (0.3 mg kg-1, i.v.) was
administered 15 or 25 min after the start of the ischaemic
period in animals subjected to IPost applied 10 s (LY-
IPost1000 group, n = 6) or 10 min after reperfusion onset
(LY-IPost100 group, n = 6), respectively. JAK/STAT
pathway inhibitor AG490 (3 mg kg-1, i.v.) was adminis-
tered 15 or 25 min after the start of the ischaemic period in
animals subjected to IPost applied 10 s (AG-IPost1000
group, n = 6) or 10 min after reperfusion onset (AG-
IPost100 group, n = 6), respectively. The doses and tim-
ings of PD-98059, LY-294002 and AG490 applications
were selected on the basis of previously published studies
[43, 48].
Immunoblotting for survival kinases
In an additional set of experiments, rats underwent 30 min
of myocardial ischaemia and the hearts were collected at
15 min after sham-IPost or IPost (six cycles of I/R, 10 s/
10 s) applied 10 s, 10 min or 45 min after reperfusion
onset. Rats were randomly assigned to one of the following
six groups: sham-immediate IPost (sham-IPost1000, n = 6),
immediate IPost (IPost1000, n = 6), sham-early IPost
(sham-IPost100, n = 6), early IPost (IPost100, n = 6),
sham-delayed IPost (sham-IPost450, n = 6) and delayed
Fig. 2 a Illustration of the experimental protocols. Arrow indicates
time of intravenous administration of the inhibitors of RISK [PD-
98059 (PD), LY-294002 (LY)] or SAFE pathways [AG490 (AG)].
b PD and LY abolished cardioprotection established by immediate
IPost (IPost1000), but had no effect on cardioprotection conferred by
early IPost (IPost100). AG had no effect on the immediate or early
IPost cardioprotection. Infarct sizes are presented as percentages of
the areas at risk. Individual data and mean ± SD are shown.
**P \ 0.01; *P \ 0.05; n.s.—not significant
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IPost, (IPost450, n = 6). For the analysis of protein phos-
phorylation, Western blots were performed on myocardium
from the area at risk. The ventricular tissue was excised,
frozen in liquid nitrogen and stored at -80 C before the
assays. Total AKT, p42/p44 MAPK (ERK1/2), STAT3 and
their respective phospho-proteins were immunodetected
from cell lysates using specific primary antibodies (all from
Cell Signalling Technology, New England Biolabs, Hiti-
chin, UK). Proteins were resolved on SDS-PAGE gels and
transferred to polyvinylidene difluoride membranes
(Amersham Biosciences, Piscataway, USA) according to
the manufacturer’s instructions. After antibody labelling,
detection was performed (ECL detection system, Amer-
sham Biosciences, Piscataway, NJ). Densitometry was used
to calculate the ratio of phosphorylated and total protein in
IPost and respective sham groups, normalised to the
expression of b-actin or CDK4 protein (Santa Cruz, Insight
Biotechnology, Wembley, UK or Cell Signalling
Technology, New England Biolabs, Hitichin, UK) to con-
trol protein loading.
Protocol 3. To investigate the role of mitoKATP channels
in cardioprotection established by IPost.
Myocardial ischaemia/reperfusion injury was induced
by 30 min (n = 8) of LAD occlusion followed by
120 min of reperfusion. Immediate, early and delayed
IPost protocols included six cycles of I/R (10 s/10 s)
starting, respectively, 10 s (IPost1000, n = 6), 10 min
(IPost100, n = 7), 30 min (IPost300, n = 9) or 45 min
(IPost450, n = 8) after reperfusion onset (Fig. 4a). The
mitoKATP channel blocker 5-hydroxydecanoate (5-HD,
10 mg kg-1, i.v.) was administered 20 or 29 min after the
start of the ischaemia period in animals subjected to IPost
applied 10 s (5-HD-IPost1000 group; n = 6) or 10 min
after reperfusion onset (5-HD-IPost100 group; n = 6),
respectively. To determine the role of mitoKATP channels
Fig. 3 a Representative immunoblots showing total AKT and
phospho-AKT (Ser473) protein expression in left ventricular lysates
following immediate IPost (10 s after reperfusion onset), early IPost
(10 min after reperfusion onset), delayed IPost (45 min after reper-
fusion onset) and respective sham-IPost procedures. b Summary data
illustrating mean ± SD of the densitometry of phospho-AKT-to-AKT
ratio. c Representative immunoblots showing total p44/42 MAPK
(ERK1/2) and phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204)
protein expression in left ventricular lysates following immediate
IPost, early IPost, delayed IPost and respective sham-IPost procedure.
d Summary data illustrating mean ± SD of the densitometry of
phospho-p44/42 MAPK-to-total p44/42 MAPK ratio. e Representative
immunoblots showing total STAT3 and phospho-STAT3 (Tyr705)
protein expression in left ventricular lysates following immediate
IPost, early IPost, delayed IPost and respective sham-IPost procedure.
f Summary data illustrating mean ± SD of the densitometry of
phospho-STAT3-to-STAT3 ratio
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in cardioprotection established by delayed IPost, 5-HD
was given 20 or 35 min after the end of the ischaemia
period in animals subjected to IPost applied 30 or 45 min
after reperfusion onset, respectively (5-HD-IPost300,
n = 6 and 5-HD-IPost450, n = 6; groups). The dose and
timings of 5-HD administration were selected on the basis
of previously published reports [11].
Statistical analysis
Data are reported as mean ± SD. Data were compared by
ANOVA followed by Tukey–Kramer post hoc test or
unpaired t test, as appropriate. Values of P \ 0.05 were
considered to be significant.
Results
No differences in mean arterial blood pressure or heart rate
before or during ischaemia and reperfusion were observed
between groups of animals recruited into the experimental
protocols (data not shown). There were also no differences
in the areas at risk between experimental groups (mean
values of areas at risk ranged between 39 and 43 %).
Figures 1c, d, 2b and 4b illustrate infarct sizes expressed as
percentages of the area at risk.
Efficacy of immediate, early and delayed IPost
in conferring cardioprotection against myocardial
ischaemia/reperfusion injury and its dependence
upon the duration of the ischaemic period.
Infarct sizes in animals subjected to 20, 30 and 45 min of
LAD occlusion followed by 120 min of reperfusion were
33 ± 3, 44 ± 8, and 51 ± 8 %, respectively (Fig. 1c).
Infarcts in animals subjected to 45 min of ischaemia were
significantly larger than in animals subjected to 20 min of
ischaemia (P \ 0.05) (Fig. 1c). IPost reduced infarct sizes
by 43 % (P \ 0.01) and 31 % (P \ 0.05) when applied
either 10 s or 10 min after the end of myocardial ischaemia
which had the duration of 30 min (Fig. 1c). IPost failed to
reduce the infarct size when applied 10 s or 10 min fol-
lowing periods of myocardial ischaemia lasting either 20 or
45 min (Fig. 1c). Delayed IPost applied either 30 min or
45 min after the onset of reperfusion effectively reduced
infarct size by 36 % (P \ 0.01) and 41 % (P \ 0.01),
respectively (Fig. 1d). IPost applied after 60 min of
reperfusion was ineffective (Fig. 1d).
The role of RISK and SAFE pathways
in cardioprotection established by IPost
To determine whether activation of RISK and SAFE path-
ways is responsible for IPost cardioprotection, we compared
the infarct sizes in rats subjected to 30 min of LAD occlu-
sion followed in 10 s or 10 min by IPost in control condi-
tions (injections of vehicle) and after systemic
administration of ERK1/2 inhibitor PD-98059, PI3K inhib-
itor LY-294002 or JAK/STAT pathway inhibitor AG490
(Fig. 2b). In the vehicle-treated group, infarct size was
43 ± 3 %. Both PD-98059 and LY-294002 abolished
Fig. 4 a Illustration of the experimental protocols. Arrow indicates
time of intravenous administration of the mitochondrial KATP channel
blocker 5-hydroxydecanoate (5-HD). b 5-HD abolished cardiopro-
tection established by immediate (IPost1000) and early (IPost100)
IPost, but had no effect on cardioprotection conferred by delayed
IPost (IPost300and IPost450). Infarct sizes are presented as percent-
ages of the areas at risk. Individual data and mean ± SD are shown.
**P \ 0.01; *P \ 0.05; n.s.—not significant
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cardioprotection induced by immediate IPost applied 10 s
after ischaemia (infarct size 44 ± 4 and 41 ± 3 %,
respectively, both P \ 0.01 vs IPost1000, Fig. 2b) but had no
effect on cardioprotection conferred by early IPost applied
10 min after reperfusion onset (infarct size 24 ± 3 and
23 ± 4 %, respectively, both n.s. vs IPost100, Fig. 2b).
AG490 had no effect on cardioprotection conferred by either
immediate or early IPost (infarct size 25 ± 3 and 25 ± 6 %,
respectively, both n.s. vs IPost1000 and IPost100, respec-
tively, Fig. 2b). Western blot analysis revealed significant
stimulatory effect of immediate IPost (10 s of reperfusion)
on AKT and ERK1/2 (p42/p44 MAPK) phosphorylation
(Fig. 3). Early (10 min of reperfusion) or delayed (45 min of
reperfusion) IPost had no effect on phosphorylation of AKT,
p42/p44 MAPK or STAT3 (Fig. 3).
The role of mitoKATP channels in cardioprotection
established by IPost
To determine if the activity of mitoKATP channels contrib-
utes to IPost cardioprotection, we compared the infarct sizes
in rats subjected to 30 min of LAD occlusion followed in
10 s, 10 min, 30 min or 45 min by IPost (Fig. 4). In the
vehicle-treated group, infarct size was 44 ± 5 %. 5-HD
abolished cardioprotection induced by IPost applied 10 s or
10 min after ischaemic period (infarct size 37 ± 6, and
41 ± 3 %, respectively, both P \ 0.05 vs IPost1000 and
IPost100) but had no effect on cardioprotection conferred by
delayed IPost, applied 30 or 45 min after reperfusion onset
(Fig. 4b).
Discussion
This study reveals the existence of distinct mechanisms
underlying cardioprotection induced by immediate, early
and delayed postconditioning. We confirmed in a rat model
of myocardial infarction that delayed IPost confers signif-
icant cardioprotection even if applied 45 min after reper-
fusion onset. Efficacy of cardioprotection induced by IPost
is critically dependent upon the duration of the prior
ischaemic insult. Cardioprotection induced by immediate
and early postconditioning involves recruitment of RISK
pathway and/or activation of mitoKATP channels, while
delayed postconditioning appears to rely on a different
mechanism(s).
Delayed postconditioning, duration of ischaemia
and the importance of early reperfusion
for cardioprotective interventions
Since the phenomenon of IPost was first described [51],
efficacy of cardioprotection induced by ischaemic
postconditioning was demonstrated in various experimental
models using mouse, rat and rabbit hearts in vivo and
in vitro, as well as dogs and pigs in vivo [40]. However,
negative results were also obtained in the experiments
conducted in pigs [38] and rats [4, 6, 26]. Although, most
of the rat studies which used experimental protocols
involving myocardial ischaemia lasting 30–40 min repor-
ted significant cardioprotection induced by IPost [43, 44,
48], there are reports that IPost may not be effective in this
paradigm [4, 6, 26]. Tang et al. (2006) [44] demonstrated in
conscious rats that IPost is capable of conferring cardio-
protection only if duration of ischaemia is less than 45 min.
In the present study immediate (applied 10 s into
reperfusion period) and early (applied 10 min into reper-
fusion) IPost effectively reduced myocardial injury only
when applied after a period of ischaemia lasting 30 min.
IPost had no effect on infarcts which developed following
LAD occlusion for either 20 or 45 min. When duration of
ischaemia was 30 min, IPost was effective in establishing
cardioprotection when applied as early as 10 s and as late
as 45 min after reperfusion onset, suggesting that the effi-
cacy of IPost is critically dependent upon the duration of a
prior ischaemic period. These data are in agreement with
the results of Roubille et al. [35] who demonstrated in a
mouse model that IPost confers significant cardioprotection
when applied 30 min into the reperfusion. However, these
data are discordant with the results of Kin et al. [22] who
used a similar MI model in rats and reported complete lack
of cardioprotection when IPost was applied 1 min after the
onset of reperfusion, suggesting that significant proportion
(23 %) of the affected myocardial tissue is irreversibly
damaged during the first minute of reflow. The
reason(s) for this discrepancy between two studies con-
ducted under similar experimental conditions are unknown.
In vivo data which demonstrate the importance of early
reperfusion as a window for cardioprotection are surpris-
ingly sparse. Yang et al. [49] reported in a rabbit model of
MI that application of IPost 10 min after onset of reper-
fusion is no longer effective. However, studies in mice
[10], rabbits [1], and dogs [8], showed reduction in infarct
size by IPost applied 1 min into the reperfusion period.
It has been suggested a decade ago that immediate (very
early) period of reperfusion represents the last window of
opportunity when cardioprotective treatments could be
applied [32]. It is believed that irreversible damage of
cardiomyocytes is triggered by opening of the mPTP,
which occurs during the first minutes of reperfusion and
plays central role in lethal reperfusion injury [1, 5, 10, 13,
19]. Accordingly, preventing mPTP opening either phar-
macologically [3, 10] or by application of IPost [1, 29]
should reduce lethal myocardial reperfusion injury. How-
ever, conflicting data were obtained when mPTP opening
was blocked pharmacologically. mPTP inhibitor
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cyclosporine A failed to reduce infarct size when admin-
istered just before the onset of reperfusion in rats [4] and
pigs [21]. Opposite data were obtained in humans [31] as
well as pig [39] and mouse [3] models which demonstrated
reduction in infarct size following cyclosporine A
administration.
Recent study suggested that mPTP opening and its role
in reperfusion-induced cell death may be dependent upon
the duration of the prior ischaemic insult [37]. This study
demonstrated that mPTP opening mediates lethal myocar-
dial injury following prolonged periods of ischaemia
(50 min), while its role appears to be less significant when
the duration of ischaemia is limited to 30 min. These data
suggest that death of cardiomyocytes induced by shorter
periods of ischaemia followed by reperfusion may be
triggered by mechanisms other than mPTP opening. This
idea is supported by the results of another recent study
which suggested two distinct phases of reperfusion injury
[33]. It was reported that following an acute MI, lactate
dehydrogenase is released in two separate peaks occurring
2–20 min and 30–120 min of reperfusion, suggesting the
existence of two different phases of reperfusion injury.
Significant correlation was only observed between the
second peak of lactate dehydrogenase release and the
resultant infarct size.
Together, recent evidence and our results indicate that
early period of reflow may not be the last window of
opportunity for cardioprotection and under certain condi-
tions myocardial injury can be reduced by procedures/
treatments applied with a significant delay after the
reperfusion onset. The data support the idea of a ‘‘dynamic
wavefront of reperfusion-induced cell death’’ proposing
that lethal myocardial injury develops over time during the
reperfusion period [35]. In support of this view, we
recently demonstrated in a rat MI model that remote
ischaemic postconditioning (femoral artery occlusion)
applied 10 min after the onset of reperfusion is also
effective in reducing infarct size [2].
The role of RISK, SAFE pathway(s) and mitoKATP
channels in the mechanisms underlying delayed
postconditioning
Recruitment of PI3K-AKT and the p42/p44 MAPK
(ERK1/2), known as RISK pathway, follows activation of
sarcolemmal receptors by G-protein-coupled ligands or
growth hormones [12]. This results in mPTP inhibition
mediated via phosphorylation and subsequent inhibition of
glycogen synthase kinase 3b (GSK3b) [20]. Activation of
RISK pathway is believed to be central in the mechanisms
underlying IPost cardioprotection in rats [14, 48]. In this
study, pharmacological blockade of RISK pathway abol-
ished cardioprotection induced by immediate IPost but had
no effect on cardioprotection conferred by IPost applied
10 min after the onset of reperfusion. These effects are
consistent with the Western blot analysis of survival kinase
expression which demonstrated that only immediate IPost
(but not early or delayed IPost) facilitates AKT and p42/
p44 MAPK phosphorylation. JAK/STAT pathway inhibitor
AG490 had no effect on cardioprotection induced by either
immediate or early IPost and both postconditioning para-
digms had no significant effect on STAT3 phosphoryla-
tion—the result consistent with the data reported in the
literature [43]. Together, these data suggest that activation
of RISK pathway may only contribute to cardioprotection
induced by immediate IPost, while cardioprotection
established by early and delayed IPost rely on different
mechanism(s).
One of the possible mechanisms of IPost cardioprotec-
tion may involve recruitment of mitoKATP channels [30].
In the present study, blockade of mitoKATP channels
(systemic application of 5-HD) abolished cardioprotection
established by IPost applied 10 s or 10 min, but had no
effect on cardioprotection when delayed IPost was applied
30 and 45 min after the onset of reperfusion. Although the
exact role of mitoKATP channels in cardioprotection is not
yet clear [9], our pharmacological analysis of the mecha-
nisms underlying immediate, early and delayed IPost
suggests the existence of distinct mechanisms underlying
these cardioprotective phenomena.
Clinical relevance
Results of several published animal studies taken together
with the data reported here indicate that the efficacy of
IPost in inducing cardioprotection is critically dependent
on the duration of the preceding ischaemic insult. This may
explain the discordant results of human studies which
assessed myocardial damage and showed either a signifi-
cant reduction in infarct size [25, 27, 46, 47], or no effect
[7, 45] of IPost. Lack of IPost beneficial effect could be
explained by cardiovascular risk factors, pharmacological
treatment(s) and various co-morbidities, as previously
suggested [17, 50]. Inclusion criteria in some published
clinical studies included duration of ischaemia of more
than 6 h [7]. Hedstrom et al. [15] performed a comparative
analysis of the first time MI evolution in man and the most
common experimental animals. The time to reach 50 %
infarct size of the area at risk in pigs was found to be
37 min, in rats—41 min, in dogs—181 min and in
humans—288 min [15]. Extrapolating rat ischaemia lasting
40–45 min to humans, a corresponding time to reach 50 %
infarct size would be *5 h. Experimental studies
(including the results reported here) suggest that IPost is
ineffective in rats if applied after such a long ischaemic
episode [40]. Therefore, inclusion of patients with long
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ischaemic time before immediate percutaneous coronary
intervention can potentially make it difficult to reveal the
beneficial effect of IPost.
Recent study by Roubille et al. [36] demonstrated that in
patients with TIMI 2–3 flow grade on admission, corre-
sponding to a delayed application of the postconditioning
algorithm, IPost had no effect on infarct size. The authors
mentioned that the mean time from the onset of symptoms to
intervention, time to hospital admission and door-to-balloon
time were similar between the two patient groups and,
therefore, cannot explain the absence of IPost beneficial
effect. However, the exact time of reperfusion onset in these
TIMI 2–3 flow grade patients cannot be accurately deter-
mined. Furthermore, the potential interference of coronary
microembolization with reperfusion and reperfusion
through a residual stenosis, i.e. gentle reperfusion, with
protection by IPost cannot be ruled out [16]. Coronary mi-
croembolization with reperfusion and gentle reperfusion,
both have an effect on infarct size as demonstrated in animal
models. Interestingly, previous study conducted in patients
with STEMI and reported by the same group demonstrated
that thrombus aspiration had no effect on the beneficial
effect of IPost, suggesting that a delay of several minutes
does not abolish cardioprotection induced by IPost [27].
In accord with current guidelines of STEMI manage-
ment, most patients undergo coronary thrombectomy first
[42] and this may delay application of the first angioplasty
balloon inflation of the IPost algorithm beyond the first
minutes of reflow. Noman et al. [28] reported that the
association between thrombectomy and reduced long-term
mortality is only significant in patients when duration of
myocardial ischaemia is less than 180 min. This suggests
that thrombectomy may be beneficial only in a subgroup of
STEMI patients. Results of the present study suggest that
following moderate durations of ischaemia, application of
IPost with some delay (due to thrombus aspiration proce-
dure) after the coronary artery reopens might have a sig-
nificant beneficial effect in reducing the extent of
myocardial injury and improving prognosis of the patients.
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